A Phase III Double-Blind, Randomized, Placebo-Controlled Trial of Minocycline in Clinically Isolated Syndromes (CIS)
Latest Information Update: 09 Jun 2025
At a glance
- Drugs Minocycline (Primary)
- Indications Demyelinating disorders; Multiple sclerosis
- Focus Therapeutic Use
- Acronyms MinoCIS
Most Recent Events
- 01 May 2020 Results (N=28), subgroup analysis assessing effects of minocycline on circulating matrix metalloproteinases, presented at the 72nd Annual Meeting of the American Academy of Neurology
- 30 Jul 2013 Planned number of patients changed from 200 to 154 as reported by ClinicalTrials.gov.
- 30 Jul 2013 Planned end date changed from 1 Dec 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov.